Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences’ SEC filings can feel like a lab notebook written in legalese. Between intricate disclosures on FB-102’s preclinical data, detailed R&D burn rates, and frequent capital-raise provisions, even seasoned biotech investors struggle to spot what matters quickly. That’s why many search “how to read Forte Biosciences’ 10-K annual report” or “where to track Forte Biosciences insider trading Form 4 transactions.”
Stock Titan fixes that complexity. Our AI-powered summaries translate every 10-K, 10-Q quarterly earnings report, and 8-K material events into plain language, flagging cash-runway trends, clinical milestones, and potential dilution signals. Need real-time alerts? The moment a director files a Form 4, the “[Forte Biosciences Form 4 insider transactions real-time]” feed updates instantly—no EDGAR digging required. Curious about upcoming shareholder votes? Our platform links the proxy statement executive compensation tables to prior grants so you can compare packages effortlessly.
Here’s how investors use the page:
- Monitor “[Forte Biosciences quarterly earnings report 10-Q filing]” for shifts in R&D expense and cash equivalents.
- Track “[Forte Biosciences executive stock transactions Form 4]” to gauge management’s conviction.
- Read “[Forte Biosciences 8-K material events explained]” for trial readouts or financing announcements.
- Reference “[Forte Biosciences annual report 10-K simplified]” to understand risk factors and going-concern language.
Because every filing is parsed, summarized, and searchable, you spend minutes—not hours—finding answers to questions like “What does Forte Biosciences report in their SEC filings?” or “How will a new ATM program impact dilution?” Unlock the full story behind FB-102 and make informed decisions faster with Stock Titan.
Forte Biosciences (FBRX) announced a public offering of 5,630,450 shares of common stock at $12.00 per share and 619,606 pre-funded warrants at $11.999 per warrant. The total offering value is approximately $75 million, with net proceeds of $70.5 million after underwriting discounts.
Key offering details:
- Pre-funded warrants have $0.001 exercise price with no expiration
- Underwriters granted 30-day option to purchase additional 937,508 shares
- Joint book-runners: TD Cowen, Evercore ISI, Guggenheim Securities, and Chardan
The company recently reported positive Phase 1b trial results for FB102 in celiac disease, showing: statistically significant benefits in VCIEL endpoint (p=0.0099), 73% improvement in Vh:Cd ratio, and 42% reduction in GI symptoms versus placebo. FB102 is an anti-CD122 monoclonal antibody targeting autoimmune conditions, currently in trials for celiac disease and vitiligo.
Forte Biosciences (NASDAQ:FBRX) announced a significant public offering of common stock and pre-funded warrants. The company plans to issue 5,630,450 shares at $12.00 per share and 619,606 pre-funded warrants at $11.999 per warrant. The offering, expected to close around June 26, 2025, will generate approximately $75.0 million in gross proceeds (potentially $80.5 million if underwriters exercise their option). Net proceeds of approximately $70.0 million are expected to fund operations into 2027. The offering is being managed by TD Securities, Evercore, Guggenheim Securities, and Chardan Capital Markets.
FAQ
What is the current stock price of Forte Biosciences (FBRX)?
What is the market cap of Forte Biosciences (FBRX)?
What is the core focus of Forte Biosciences Inc?
What conditions is FB-102 being developed to treat?
How does Forte Biosciences approach drug development?
What makes Forte Biosciences different from other biopharmaceutical companies?
At what stage is FB-102 currently?
How does the company protect its research and innovations?
What challenges does the company face in its development process?
How can investors learn more about the company?
